IMUX
ImmunicDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Immunic now has a meaningfully improved cash position after the February 2026 private placement, removing the most immediate financing pressure, while the late-2026 ENSURE readout offers substantial re-rating potential if efficacy and safety support the RMS thesis [#10-K-2026-02-26].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.0.
What can break
Future capital structure complexity, including warrant-related overhang, could restrain upside even after financing.
Momentum
94
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $1.80 · Bear $0.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $4.57
Why
Momentum94 · Δ7d +3.0
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendImproving
Δ7d
+3.0
Δ21d
+40.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 93.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$206.09M
Beta
1.57
Shares Out
120.28M
P/E (TTM) · Derived
-2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.52
Rev YoY
-
EPS YoY
+45.2%
Gross Margin
-
Op Margin
-
Net Debt
-$35.67M
Current Ratio
1.31
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology